November 9, 2024Poster presentation SITC Annual Meeting 2024, HoustonIdentification of PD1-IL2(TAP) – a PD-1 Blocking Immunoconjugate Harboring a Tumor-Activatable Masked IL-2 Payload Lacking Binding to IL2Rbeta/CD122Read MoreApril 9, 2024Poster presentation AACR Annual Meeting 2024, San DiegoThe first-in-class PD1-IL18 conjugate BPT567 induces potent anti-tumor immunity by preferentially activating PD1+IL18R+ intratumoral effector T cells in cisRead MoreApril 17, 2023Poster presentation AACR Annual Meeting 2023, OrlandoA First-in-Class PD1-IL18 Immunocytokine (BPT567) Targets PD-1+ IL18R+ CD8+ T Effector Cells Enriched in the Tumor Microenvironment and Exhibits Potent Antitumor Efficacy With Excellent TolerabilityRead MoreFebruary 3, 2023Poster presentation, selected flash talk and prize winner at the 3rd Swiss Cytometry Meeting, ZürichAn algorithm-aided flow cytometry data analysis pipeline to analyze non-human primate immunomonitoring data in large moleculeRead MoreNovember 10, 2022Poster presentation SITC Annual Meeting 2022, BostonGeneration of a Highly Potent, Cis-signaling PD1-IL2 Immunocytokine Using a Novel Chemical Synthesis and Conjugation PlatformRead MoreNovember 10, 2022Poster presentation SITC Annual Meeting 2022, BostonUsing Site-Specific Chemical Conjugation to Generate Superior Half-Life Extended or PD1-Targeted Formats of a Potent IL-18 Variant Resistant to IL-18 Binding ProteinRead MoreOctober 21, 2022Poster presentation 10th International Conference on Autoimmunity: Mechanisms and Novel Treatments Identification of BPT323Identification of BPT323 – An immunocytokine for treatment of autoimmune diseases combining orthogonal modes of action of TNFα blockade and selective Treg expansionRead MoreOctober 21, 2022Poster presentation 10th International Conference on Autoimmunity: Mechanisms and Novel TreatmentsIdentification of BPT264 – A potent alpha-enhanced/beta-dead and half-life-extended IL-2 Treg enhancer for treatment of autoimmune diseasesRead MoreApril 13, 2022Poster presentation AACR Annual Meeting 2022, New OrleansCis-activation of PD-1+ effector T cells with dual-targeting immunocytokines generated using a novel chemical conjugation platform. AACR Annual Meeting 2022, New OrleansRead MoreApril 13, 2022Poster presentation AACR Annual Meeting 2022, New OrleansBPT-143: A fully synthetic alpha-dead IL-2 with a best-in-class preclinical pharmacodynamic and efficacy profile supporting first-in-human clinical development. AACR Annual Meeting 2022, New OrleansRead More
'